is_manufactured_by has function has role has component vaccinated in route immunizes against disease immunizes recipient immunizes against pathogen has drug brand name haemophilus meningitis Homo sapiens ActHIB vaccine 103935 Preparation: The vaccine consists of the Haemophilus b capsular polysaccharide (polyribosyl-ribitol-phosphate, PRP), a high molecular weight polymer prepared from the Haemophilus influenzae type b (HiB) strain 1482 grown in a semi-synthetic medium, covalently bound to tetanus toxoid. The tetanus toxoid is prepared by extraction, ammonium sulfate purification, and formalin inactivation of the toxin from cultures of Clostridium tetani (Harvard strain) grown in a modified Mueller and Miller medium. The toxoid is filter sterilized prior to the conjugation process. When ActHIB vaccine is reconstituted with saline diluent, each single dose of 0.5 mL is formulated to contain 10 mu g of purified capsular polysaccharide conjugated to 24 mu g of inactivated tetanus toxoid, and 8.5% of sucrose (ActHIB 2005). Reference: http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=157&keywords= 157 VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=157 Oliver He Kallan Roan PMID:1735812 PMID:1517908 ActHIB ActHIB vaccine is indicated for the active immunization of infants and children 2 months through 5 years of age for the prevention of invasive disease caused by H influenzae type b. https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm174743.htm vaccine https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM109841.pdf FDA licensed vaccine role conjugate vaccine intramuscular route USA licensed human vaccine preventive vaccine function prophylactic vaccine conjugate vaccine role Haemophilus influenzae serotype b vaccine Canada licensed human vaccine Haemophilus influenzae serotype b Canada licensed vaccine role capsular polysaccharide of pathogen organism as vaccine component vaccine conjugate protein vaccine monovalent role licensed human haemophilus influenzae serotype b vaccine Sanofi Pasteur, SA ActHIB